Vanda Pharmaceuticals (NASDAQ:VNDA)
will collaborate with the University of Illinois at Chicago to
investigate small molecules for the potential treatment of COVID-19.
The partnership will include the use of a
high-throughput screening assay to identify candidates that may prevent
cathepsin-L cleavage of SARS-CoV-2 glycoproteins that are required for
viral processing in the host cell.
The company says it is also exploring drugs that
may block the virus from entering the cell at an entry point called the
angiotensin converting enzyme 2 receptor and drugs that inhibit the
transmembrane protease serine 2 precursor.
The program includes the initiation of a study,
ODYSSEY, evaluating tradipitant in hospitalized severely ill patients
with COVID-19 pneumonia.
Shares up 12% after hours.
https://seekingalpha.com/news/3559497-vanda-pharma-up-12-after-hours-on-covidminus-19-drug-development-plan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.